![[KBS] 경제쇼](/media/images/podcasts/ad5df2f6-29d1-4a57-882a-28a8c6bbdbc3/ad5df2f6-29d1-4a57-882a-28a8c6bbdbc3.jpg)
10/1(목) - [핫이슈, 더 깊게] 우리가 몰랐던 중국 바이오 이야기
Summary
This episode of KBS Economy Show reviews the first day of Q4, highlighting a strong market rally driven by US inflation data and expectations of Fed rate cuts. It details Trump's unilateral announcement of Korean investment projects in nuclear and LNG, noting the lack of official confirmation from Seoul. The main segment features an expert analysis of China's rapid rise in the biotech sector, focusing on its FDA approvals, massive domestic clinical trial capacity, and new "Newco" technology export models. The discussion also covers the US Biosecure Act and its implications for global pharma…
Topics discussed
Show introduction and guest welcome
Q4 market performance: KOSPI and KOSDAQ surge
US inflation data and Fed rate cut expectations
Micron Technology earnings and semiconductor outlook
Trump's US-Korea investment project details
Rising student loans and delinquency rates
Jensen Huang on GPT-6 and the arrival of AGI
Korea's bio-industry strategy for security and growth
US Biosecure Act and impact on Chinese biotech
China's rapid FDA approvals and clinical trial speed
Factors behind China's large patient pool for trials
China's biotech technology export statistics
The 'Newco' model in Chinese biotech deals
Korea's goals to increase clinical trial share
Listen ad-free on Castria